Chu Vision Institute Illuminates the Path to Recovery: The Importance of Sunglasses After Cataract Surgery
June 24, 2024 12:19 ET
|
Chu Vision Institute
Bloomington, June 24, 2024 (GLOBE NEWSWIRE) -- Bloomington, Minnesota - In the wake of advancements in cataract surgery, Chu Vision Institute emerges as a beacon of guidance and support for those...
Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
June 24, 2024 09:27 ET
|
Spherix Global Insights
EXTON, PA., June 20, 2024, June 24, 2024 (GLOBE NEWSWIRE) -- The treatment landscape for Diabetic Macular Edema (DME) continues to evolve, with innovative therapies and emerging data significantly...
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
June 24, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functional shortened form of human complement factor H (sCFH)Complement factor...
Ikerian (parent company of RetinAI U.S. Inc.) receives EU-MDR Certificate for four devices, its Ophthalmology Data Platform and AI models
June 24, 2024 07:00 ET
|
Ikerian AG
BERN, Switzerland and BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Ikerian AG (“Ikerian”) a leader in developing software solutions for medical image and data management and artificial intelligence...
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
June 24, 2024 06:50 ET
|
ANI Pharmaceuticals, Inc.; Alimera Sciences, Inc.
Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
June 22, 2024 14:56 ET
|
Pomerantz LLP
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. (“Skye” or the “Company”) (NASDAQ: SKYE). Such investors are advised...
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
June 21, 2024 07:00 ET
|
Ocugen
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial• DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) --...
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
June 21, 2024 03:30 ET
|
Sanofi - Aventis Groupe
Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee Paris, June 21, 2024. Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi...
Global Medical Laser Systems Market Size To Worth USD 15.89 Billion By 2033 | CAGR of 13.20%
June 21, 2024 01:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , June 21, 2024 (GLOBE NEWSWIRE) -- The Global Medical Laser Systems Market Size is to Grow from USD 4.6 Billion in 2023 to USD 15.89 Billion by 2033, at a Compound Annual...
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
June 20, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...